Literature DB >> 24434353

Molecular mechanisms of congenital heart block.

Aurélie Ambrosi1, Sven-Erik Sonesson2, Marie Wahren-Herlenius3.   

Abstract

Autoantibody-associated congenital heart block (CHB) is a passively acquired autoimmune condition associated with maternal anti-Ro/SSA antibodies and primarily affecting electric signal conduction at the atrioventricular node in the fetal heart. CHB occurs in 1-2% of anti-Ro/SSA antibody-positive pregancies and has a recurrence rate of 12-20% in a subsequent pregnancy. Despite the long-recognized association between maternal anti-Ro/SSA autoantibodies and CHB, the molecular mechanisms underlying CHB pathogenesis are not fully understood, but several targets for the maternal autoantibodies in the fetal heart have been suggested. Recent studies also indicate that fetal susceptibility genes determine whether an autoantibody-exposed fetus will develop CHB or not, and begin to identify such genes. In this article, we review the different lines of investigation undertaken to elucidate the molecular pathways involved in CHB development and reflect on the hypotheses put forward to explain CHB pathogenesis as well as on the questions left unanswered and that should guide future studies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrioventricular block; Autoantibodies; Congenital heart block; La/SSB; MHC; Neonatal lupus erythematosus; Ro/SSA

Mesh:

Substances:

Year:  2014        PMID: 24434353     DOI: 10.1016/j.yexcr.2014.01.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  23 in total

Review 1.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

Review 2.  Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development.

Authors:  Laura J Yockey; Akiko Iwasaki
Journal:  Immunity       Date:  2018-09-18       Impact factor: 31.745

Review 3.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

4.  Precision medicine for autoimmune disease.

Authors:  Lucienne Chatenoud
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

5.  [Pathogenesis of systemic lupus erythematosus].

Authors:  T Alexander; A Radbruch; F Hiepe
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

6.  Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block.

Authors:  Marta Tonello; Ariela Hoxha; Elena Mattia; Alessandra Zambon; Silvia Visentin; Alessia Cerutti; Anna Ghirardello; Ornella Milanesi; Amelia Ruffatti
Journal:  Clin Rheumatol       Date:  2017-02-15       Impact factor: 2.980

7.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

8.  Prolonged Tpeak-Tend interval in anti-Ro52 antibody-positive connective tissue diseases.

Authors:  Ayse Nur Tufan; Saim Sag; Mustafa Ferhat Oksuz; Selime Ermurat; Belkis Nihan Coskun; Mustafa Gullulu; Ferah Budak; Ibrahim Baran; Yavuz Pehlivan; Ediz Dalkilic
Journal:  Rheumatol Int       Date:  2016-05-18       Impact factor: 2.631

Review 9.  Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review.

Authors:  Federica Vanoni; Sebastiano A G Lava; Emilio F Fossali; Riccardo Cavalli; Giacomo D Simonetti; Mario G Bianchetti; Marie-Ange Bozzini; Carlo Agostoni; Gregorio P Milani
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

10.  Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model.

Authors:  A Hoxha; A Ruffatti; A Ambrosi; V Ottosson; M Hedlund; L Ottosson; M Anandapadamanaban; M Sunnerhagen; S-E Sonesson; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2016-09-13       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.